Latest revision as of 01:27, 30 September 2014

Tufts iGEM 2014

Home

Team

Official Team Profile

Project

Parts

Modeling

Notebook

Safety

Attributions

Summaries

Robust biofilm formation using a cyclic-di-GMP aptamer and investigating ethics and applications of engineered bactiophage

A long, noncoding massively expressed regulatory RNA (merRNA) discovered in Bdellovibrio bacteriovorus is present in high levels during its dormant phase. The merRNA is believed to sequester cyclic-di-GMP, much like a sponge. Since cyclic-di-GMP is a second messenger for various cellular functions, including motility and biofilm formation, the Tufts iGEM team introduced this merRNA sequence into E. coli. Constitutive expression of this merRNA transcript was shown to increase biofilm formation. This property can be useful in microbe-based approaches to environmental remediation. Earlier designs for phage delivery of the merRNA to disrupt biofilms inspired an investigation into the policy surrounding engineered bacteriophage. Tufts iGEM will be convening a panel of experts from various disciplines to put forth recommendations for the responsible use of phage in therapeutic and industrial applications. A proposal will be drafted for a silk bandage containing a phage cocktail which can prevent and treat infection by antibiotic-resistant bacteria.

Ribosponge Project Description:

We have devised a method to introduce a DNA sequence which encodes an RNA aptamer (i.e. - an oligonucleotide sequence which binds to a specific molecule) into a non-pathogenic E. coli strain. We have dubbed this RNA aptamer a “ribosponge” due to its unique mode of action. The ribosponge binds cyclic di-GMP, a secondary intracellular messenger which signals bacteria to enter a persistent or biofilm state. The signal is universal among many species such as E. coli, P. aeruginosa, and M. tuberculosis. Blocking the signal of c-di-GMP by binding it with an aptamer could prevent the persistent state in these and other pathogens. In order to ferry the sequence encoding the aptamer from our non-pathogenic E. coli into other bacteria of the same species, we plan on using an M13 phage which does not kill the bacteria. The project has also inspired our collaboration with the Rathneau Institute and SYNENERGENE as we look at the feasability of developing ribosponge into a product, and examine the regulatory, legal, and ethical challenges of packing it into a bacteriophage.

Backgrounds

Methods

Sponge Lab Notebook

@@ Line 20: / Line 20: @@
 <tr heigth="15px"></tr>
 <tr heigth="75px">
 <td style="border:2px solid #0099FF;" align="center" height ="45px" bgColor=black>
@@ Line 29: / Line 28: @@
 <td style="border:2px solid #0099FF;" align="center"  height ="45px"  bgColor=black>
-<a href="https://igem.org/Team.cgi?year=2014&team_name=Tufts"style="color:#0099FF"> Official Team Profile </a></td>
+<a href="https://igem.org/Team.cgi?year=2014&team_name=Tufts"style="color:#0099FF"target="_blank"> Official Team Profile </a></td>
 <td style="border:2px solid #0099FF" align="center"  height ="45px" bgColor=black>
@@ Line 56: / Line 55: @@
 <!--end navigation menu -->
 </tr>
 </tr>
 </td>
 <tr> <td colspan="3"  height="15px"> </td></tr>
 <tr><td bgColor="#e7e7e7" colspan="3" height="1px"> </tr>
@@ Line 66: / Line 62: @@
 <tr><td width="100%">
 <a href = "https://2014.igem.org/Team:Tufts/Project#backgrounds"><h5>Jump to Backgrounds</h5></a>
 <a href = "https://2014.igem.org/Team:Tufts/Project#methods"><h5>Jump to Methods</h5></a>
 <h2> Summaries </h2>
-<p> <h3>Ribosponge Project Description:</h3> <br>
+<tr> <td width="100%">
+<h3>Robust biofilm formation using a cyclic-di-GMP aptamer and investigating ethics and applications of engineered bactiophage</h3>
+A long, noncoding massively expressed regulatory RNA (merRNA) discovered in Bdellovibrio
+bacteriovorus is present in high levels during its dormant phase. The merRNA is believed to sequester
+cyclic-di-GMP, much like a sponge. Since cyclic-di-GMP is a second messenger for various cellular
+functions, including motility and biofilm formation, the Tufts iGEM team introduced this merRNA
+sequence into E. coli. Constitutive expression of this merRNA transcript was shown to increase biofilm
+formation. This property can be useful in microbe-based approaches to environmental remediation.
+Earlier designs for phage delivery of the merRNA to disrupt biofilms inspired an investigation into the
+policy surrounding engineered bacteriophage. Tufts iGEM will be convening a panel of experts from
+various disciplines to put forth recommendations for the responsible use of phage in therapeutic and
+industrial applications. A proposal will be drafted for a silk bandage containing a phage cocktail which
+can prevent and treat infection by antibiotic-resistant bacteria.
+</td></tr>
+<tr><td>
+<p> <h3>Ribosponge Project Description:</h3>
 We have devised a method to introduce a DNA sequence which encodes an RNA aptamer (i.e. - an
 oligonucleotide sequence which binds to a specific molecule) into a non-pathogenic E. coli strain. We
@@ Line 84: / Line 96: @@
 ethical challenges of packing it into a bacteriophage.</p>
 </td> </tr>
-<br>
-<tr> <td width="100%">
-<h3>Synthetic Antibody Proposal</h3> <br>
+<!--<tr> <td width="100%">
+<h3>Synthetic Antibody Proposal</h3>
 Monoclonal antibodies are proteins produced by the immune system to selectively bind
 foreign molecules and induce immune response. Given
@@ Line 106: / Line 117: @@
 antibodies in a proof-of-concept experiment, in which our synthetic antibody will be used to
 detect proteins on the surface of a cell.
-The creation of synthetic antibodies in
+The creation of synthetic antibodies in bacteria will allow researchers to circumvent the
-bacteria will allow researchers to circumvent the
+expensive, time consuming, and arduous process of monoclonal antibody production. The highly
-expensive, time consuming, and arduous process
+modular “plug-and-play” aspect of our template plasmid will make this tool simple to use and highly versatile, while the use of the constant
-of monoclonal antibody production. The highly
+region of a monoclonal antibody as the detection method will make this technology particularly powerful, as there already exists a large amount of chemistry, and protocols associated with different uses of the conserved domain. Thus, synthetic antibodies will provide yet another versatile tool for creating detection assays, diagnostics, and potentially even therapeutics for diseases such as cancers and autoimmune diseases.
-modular “plug-and-play” aspect of our template
-plasmid will make this tool simple to use and highly versatile, while the use of the constant
-region of a monoclonal antibody as the detection method will make this technology particularly
-powerful, as there already exists a large amount of chemistry, and protocols associated with different uses of the conserved domain. Thus, synthetic antibodies will provide yet another versatile tool for creating detection assays, diagnostics, and potentially even therapeutics for diseases such as cancers and autoimmune diseases.
 </td></tr>
 <br><br>
-<tr> <td width="100%">
+-->
-<h3>Robust biofilm formation using a cyclic-di-GMP aptamer and investigating ethics and applications of engineered bactiophage</h3> <br>
-A long, noncoding massively expressed regulatory RNA (merRNA) discovered in Bdellovibrio
-bacteriovorus is present in high levels during its dormant phase. The merRNA is believed to sequester
-cyclic-di-GMP, much like a sponge. Since cyclic-di-GMP is a second messenger for various cellular
-functions, including motility and biofilm formation, the Tufts iGEM team introduced this merRNA
-sequence into E. coli. Constitutive expression of this merRNA transcript was shown to increase biofilm
-formation. This property can be useful in microbe-based approaches to environmental remediation.
-Earlier designs for phage delivery of the merRNA to disrupt biofilms inspired an investigation into the
-policy surrounding engineered bacteriophage. Tufts iGEM will be convening a panel of experts from
-various disciplines to put forth recommendations for the responsible use of phage in therapeutic and
-industrial applications. A proposal will be drafted for a silk bandage containing a phage cocktail which
-can prevent and treat infection by antibiotic-resistant bacteria.
-</td></tr>
 <tr> <td>
 <a name="backgrounds"> <h2> Backgrounds </h2> </a>
 </td> </tr>
 <tr><td>
 <a name="methods"><h2>Methods</h2></a>
+<!--<a href = "https://static.igem.org/mediawiki/2014/2/24/LabNotebookAntibodyiGEM2014.pdf"> Antibody Lab Notebook </a> <br>-->
+<a href="https://static.igem.org/mediawiki/2014/a/a1/LabNotebookSpongeiGEM2014.pdf" target="_blank"> Sponge Lab Notebook </a>
 </td></tr>